Fortress Biotech Inc expected to post a loss of $1.22 a share - Earnings Preview

Fortress Biotech

07/08/2024 03:05

* Fortress Biotech Inc  FBIO.OQ   FBIO.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 8
(estimated) for the period ending June 30 2024
    * The Bay Harbor Islands Florida-based  company is expected
to
report a 15.0% decrease in revenue to $14.773 million from
$17.39 million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fortress Biotech Inc is
for a
loss of $1.22 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fortress
Biotech
Inc is $10.00​, above​ its last closing price of $1.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.69       -1.73      -1.03     Beat    40.5
 Dec. 31 2024  -1.67       -1.97      -1.28     Beat    34.9
 Jan. 1 0001   -3.12       -3.21      -0.94     Beat    70.7​
 Jun. 30 2023  -3.31       -3.41      -3.60     Missed  -5.5
 ​​Mar.        -3.38       -3.00      -3.15     Missed  -5
 31 2023                                                
 Jan. 1 0001   -3.43       -3.37      -4.46     Missed  -32.2​
 Sep. 30 2022  -3.18       -4.05      -3.75     Beat    7.4
 Jun. 30 2022  -3.28       -3.15      -3.60     Missed  -14.3
 This summary was machine generated August 7 at 02:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)